{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:12:50Z","timestamp":1784034770335,"version":"3.55.0"},"posted":{"date-parts":[[2026,7,10]]},"group-title":"Immunology","reference-count":74,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>People with cystic fibrosis (pwCF) are at increased risk of severe disease following respiratory viral infections including influenza and respiratory syncytial virus, and were therefore given priority for COVID-19 vaccination. Retrospective epidemiological data have revealed a lower incidence of SARS-CoV-2 infection and a reduced fatality rate among pwCF than in the general population, possibly from the stringent infection control measures and early adoption of protective behaviors. Despite several reports of adequate binding and neutralizing titers after vaccination, the molecular features of vaccine-elicited serum antibody repertoires in pwCF remain unknown.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed high-resolution proteomic analysis of serum IgG, combined with next-generation sequencing of B cells, to quantitatively profile Spike (S)-reactive serological repertoires from nine infection-na\u00efve pwCF after two doses of COVID-19 mRNA vaccine. We recombinantly expressed 20 IgG clonotypes from 6 pwCF as monoclonal antibodies (mAbs) and measured their binding and neutralization against vaccine-strain and variant viruses.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    All donors mounted strong binding and neutralizing titers to vaccine-strain virus. Ig-Seq revealed diverse serum repertoires in all vaccinees, with antibodies targeting the receptor-binding domain (RBD) comprising 64% of each circulating repertoire by abundance. Several serum IgG clonotypes identified across our cohort shared identical or similar\n                    <jats:italic>IGHV<\/jats:italic>\n                    and CDRH3 amino acid sequences with serum IgG from other pwCF or S-reactive mAbs isolated from non-CF individuals. These \u2018convergent\u2019 antibodies made up 14.6% of the anti-S repertoires in our cohort, reaching 24.8% in one pwCF. Convergent antibodies tended to be RBD-reactive and enriched in specific\n                    <jats:italic>IGHV<\/jats:italic>\n                    ; surprisingly, a higher abundance of convergent antibodies in serum correlated with a lower breadth of serum neutralization. All 20 mAbs bound Wuhan S with high affinity (EC\n                    <jats:sub>50<\/jats:sub>\n                    &lt; 10 nM), and only RBD-reactive mAbs conferred neutralization to vaccine or variant pseudovirus. While most mAbs bound both the B.1.617.2 (Delta, 17\/20) and B.1.1.529 (Omicron, 12\/20) strains, convergent mAbs were less likely to bind either variant.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Post-vaccine serum IgG repertoires in pwCF are dominated by RBD-focused, high-affinity antibodies and include a substantial convergent component shared with non-CF vaccinees. These findings demonstrate that pwCF mount antibody responses comparable to the general population, and a large group of convergent antibodies may contribute to strain-specific rather than cross-variant immunity.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.07.08.737356","type":"posted-content","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:05:17Z","timestamp":1783728317000},"source":"Crossref","is-referenced-by-count":0,"title":["Molecular-level analysis of serum IgG repertoires in COVID-19-vaccinated people with cystic fibrosis identifies abundant convergent antibodies"],"prefix":"10.64898","author":[{"given":"Steven","family":"Ionov","sequence":"first","affiliation":[{"name":"Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth I.","family":"Connor","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Curtis","sequence":"additional","affiliation":[{"name":"Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungmin","family":"Shin","sequence":"additional","affiliation":[{"name":"Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Koehne","sequence":"additional","affiliation":[{"name":"Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Ye","family":"Park","sequence":"additional","affiliation":[{"name":"BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Ashare","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dartmouth Health, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-3621","authenticated-orcid":false,"given":"Jiwon","family":"Lee","sequence":"additional","affiliation":[{"name":"Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA"},{"name":"BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea"},{"name":"Department of Convergence Medicine, Korea University College of Medicine, Seoul, Republic of Korea"},{"name":"Vaccine Innovation Center, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026071405300678000_2026.07.08.737356v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2715"},{"key":"2026071405300678000_2026.07.08.737356v1.2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1374"},{"key":"2026071405300678000_2026.07.08.737356v1.3","doi-asserted-by":"publisher","DOI":"10.1136\/thx.47.2.109"},{"key":"2026071405300678000_2026.07.08.737356v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412273112602"},{"key":"2026071405300678000_2026.07.08.737356v1.5","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0496(199812)26:6<371::AID-PPUL1>3.0.CO;2-N"},{"key":"2026071405300678000_2026.07.08.737356v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80008-8"},{"key":"2026071405300678000_2026.07.08.737356v1.7","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.11.1115"},{"key":"2026071405300678000_2026.07.08.737356v1.8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03067"},{"key":"2026071405300678000_2026.07.08.737356v1.9","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2213-2600(20)30177-6","article-title":"Impact of COVID-19 on people with cystic fibrosis","volume":"8","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026071405300678000_2026.07.08.737356v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.03.017"},{"key":"2026071405300678000_2026.07.08.737356v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.11.021"},{"key":"2026071405300678000_2026.07.08.737356v1.12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jcf.2021.03.028","article-title":"COVID-19 vaccine prioritisation for people with cystic fibrosis","volume":"20","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026071405300678000_2026.07.08.737356v1.13","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01528-0"},{"key":"2026071405300678000_2026.07.08.737356v1.14","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.jcf.2022.06.006","article-title":"Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study","volume":"21","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026071405300678000_2026.07.08.737356v1.15","first-page":"1144","article-title":"Estimates of SARS-CoV-2 Hospitalization and Fatality Rates in the Prevaccination Period, United States","volume":"30","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"2026071405300678000_2026.07.08.737356v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.06.004"},{"key":"2026071405300678000_2026.07.08.737356v1.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078583"},{"key":"2026071405300678000_2026.07.08.737356v1.18","first-page":"858","article-title":"Increased Safety Behavior and COVID-19-Related Fear in Adults with Cystic Fibrosis during the Pandemic","volume":"10","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"2026071405300678000_2026.07.08.737356v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(84)80946-4"},{"key":"2026071405300678000_2026.07.08.737356v1.20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1203\/00006450-198712000-00020","article-title":"Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens","volume":"22","year":"1987","journal-title":"Pediatr Res"},{"key":"2026071405300678000_2026.07.08.737356v1.21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1203\/00006450-198605000-00015","article-title":"Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency","volume":"20","year":"1986","journal-title":"Pediatr Res"},{"key":"2026071405300678000_2026.07.08.737356v1.22","doi-asserted-by":"crossref","unstructured":"Rossi E , Lausen M , Friesg\u00e5rd \u00d8bro N , Colque A , Nielsen BU , M\u00f8ller R , et al. Cystic fibrosis systemic immune profile is associated with lung microbes and characterized by widespread alterations in the innate and adaptive immune compartments. bioRxiv. 2023:2023.08.23.553085.","DOI":"10.1101\/2023.08.23.553085"},{"key":"2026071405300678000_2026.07.08.737356v1.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2026071405300678000_2026.07.08.737356v1.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2026071405300678000_2026.07.08.737356v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2020.09.037"},{"key":"2026071405300678000_2026.07.08.737356v1.26","first-page":"1010105","article-title":"Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape","volume":"13","year":"2022","journal-title":"Front Immunol"},{"key":"2026071405300678000_2026.07.08.737356v1.27","doi-asserted-by":"crossref","unstructured":"Voss WN , Mallory MA , Byrne PO , Marchioni JM , Knudson SA , Powers JM , et al. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination. Cell Reports Medicine. 2024.","DOI":"10.1101\/2024.01.22.576742"},{"key":"2026071405300678000_2026.07.08.737356v1.28","doi-asserted-by":"crossref","unstructured":"Curtis NC , Shin S , Hederman AP , Connor RI , Wieland-Alter WF , Ionov S , et al. Characterization of SARS-CoV-2 Convalescent Patients\u2019 Serological Repertoire Reveals High Prevalence of Iso-RBD Antibodies. bioRxiv. 2023:2023.09.08.556349.","DOI":"10.1101\/2023.09.08.556349"},{"key":"2026071405300678000_2026.07.08.737356v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.03.019"},{"key":"2026071405300678000_2026.07.08.737356v1.30","doi-asserted-by":"crossref","first-page":"101267","DOI":"10.1016\/j.xcrm.2023.101267","article-title":"SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes","volume":"4","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026071405300678000_2026.07.08.737356v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.11.004"},{"key":"2026071405300678000_2026.07.08.737356v1.32","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1080\/22221751.2022.2105261","article-title":"Comparative global B cell receptor repertoire difference induced by SARS-CoV-2 infection or vaccination via single-cell V(D)J sequencing","volume":"11","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"2026071405300678000_2026.07.08.737356v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.09.002"},{"key":"2026071405300678000_2026.07.08.737356v1.34","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg5268"},{"key":"2026071405300678000_2026.07.08.737356v1.35","doi-asserted-by":"crossref","first-page":"113150","DOI":"10.1016\/j.celrep.2023.113150","article-title":"Light chain of a public SARS-CoV-2 class-3 antibody modulates neutralization against Omicron","volume":"42","year":"2023","journal-title":"Cell Rep"},{"key":"2026071405300678000_2026.07.08.737356v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112370"},{"key":"2026071405300678000_2026.07.08.737356v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2023.04.010"},{"key":"2026071405300678000_2026.07.08.737356v1.38","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/s41467-021-24514-w","article-title":"Potent and protective IGHV3-53\/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2","volume":"12","year":"2021","journal-title":"Nat Commun"},{"key":"2026071405300678000_2026.07.08.737356v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32232-0"},{"key":"2026071405300678000_2026.07.08.737356v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24123-7"},{"key":"2026071405300678000_2026.07.08.737356v1.41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4224"},{"key":"2026071405300678000_2026.07.08.737356v1.42","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/j.jcf.2022.04.004","article-title":"Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis","volume":"21","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026071405300678000_2026.07.08.737356v1.43","doi-asserted-by":"crossref","unstructured":"Lucca F , Bezzerri V , Danese E , Olioso D , Peserico D , Boni C , et al. Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation. International Journal of Molecular Sciences 2023.","DOI":"10.3390\/ijms24020908"},{"key":"2026071405300678000_2026.07.08.737356v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.05.041"},{"key":"2026071405300678000_2026.07.08.737356v1.45","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.3390\/biomedicines10081998","article-title":"Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies","volume":"10","year":"2022","journal-title":"Biomedicines"},{"key":"2026071405300678000_2026.07.08.737356v1.46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.832533"},{"key":"2026071405300678000_2026.07.08.737356v1.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03324-6"},{"key":"2026071405300678000_2026.07.08.737356v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.013"},{"key":"2026071405300678000_2026.07.08.737356v1.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01676-0"},{"key":"2026071405300678000_2026.07.08.737356v1.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04060-7"},{"key":"2026071405300678000_2026.07.08.737356v1.51","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe0240"},{"key":"2026071405300678000_2026.07.08.737356v1.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.01.010"},{"key":"2026071405300678000_2026.07.08.737356v1.53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41421-021-00295-w","article-title":"Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries","volume":"7","year":"2021","journal-title":"Cell Discov"},{"key":"2026071405300678000_2026.07.08.737356v1.54","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd2321"},{"key":"2026071405300678000_2026.07.08.737356v1.55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2456-9"},{"key":"2026071405300678000_2026.07.08.737356v1.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109604"},{"key":"2026071405300678000_2026.07.08.737356v1.57","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa739"},{"key":"2026071405300678000_2026.07.08.737356v1.58","doi-asserted-by":"crossref","first-page":"eabn8590","DOI":"10.1126\/sciimmunol.abn8590","article-title":"SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine","volume":"7","year":"2022","journal-title":"Sci Immunol"},{"key":"2026071405300678000_2026.07.08.737356v1.59","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abp8328"},{"key":"2026071405300678000_2026.07.08.737356v1.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.06.015"},{"key":"2026071405300678000_2026.07.08.737356v1.61","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi9915"},{"key":"2026071405300678000_2026.07.08.737356v1.62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1317793111"},{"key":"2026071405300678000_2026.07.08.737356v1.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.025"},{"key":"2026071405300678000_2026.07.08.737356v1.64","doi-asserted-by":"crossref","first-page":"103564","DOI":"10.1016\/j.isci.2021.103564","article-title":"Sequence and functional characterization of a public HIV-specific antibody clonotype","volume":"25","year":"2022","journal-title":"iScience"},{"key":"2026071405300678000_2026.07.08.737356v1.65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247253"},{"key":"2026071405300678000_2026.07.08.737356v1.66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035497"},{"key":"2026071405300678000_2026.07.08.737356v1.67","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.024"},{"key":"2026071405300678000_2026.07.08.737356v1.68","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0826"},{"key":"2026071405300678000_2026.07.08.737356v1.69","doi-asserted-by":"publisher","DOI":"10.1021\/ac4037679"},{"key":"2026071405300678000_2026.07.08.737356v1.70","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu393"},{"key":"2026071405300678000_2026.07.08.737356v1.71","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb7269"},{"key":"2026071405300678000_2026.07.08.737356v1.72","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00700-11"},{"key":"2026071405300678000_2026.07.08.737356v1.73","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","year":"2020","journal-title":"Nat Microbiol"},{"key":"2026071405300678000_2026.07.08.737356v1.74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618685"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.07.08.737356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:30:15Z","timestamp":1784032215000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.07.08.737356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":74,"URL":"https:\/\/doi.org\/10.64898\/2026.07.08.737356","relation":{},"subject":[],"published":{"date-parts":[[2026,7,10]]},"subtype":"preprint"}}